Homepage - Pharmadigz

Biomea Fusion made a bold move, as it announced today, May 5th of 2025, that it had decided to reduce its workforce, and one of the reasons being was to conserve cash. This cost-cutting measure is going to allow it be in a position to fund its operations into...

Biomea Takes Workforce Reduction Play Of 35% For Realignment Plans

Biomea Fusion made a bold move, as it announced today, May 5th of 2025, that it had decided to...

Pliant Takes Late-Stage Route After Bexotegrast Issue And Slashes Workforce by 45%

Just the other day, Pliant Therapeutics announced that it would enact a strategic restructuring of its workforce in order...

Immunic Might Still Have Path Forward In PMS After Primary Endpoint Miss

Immunic reported data today from its phase 2 CALLIPER trial for its drug vidofludimus calcium (IMU-838) for the treatment...

Abeona Receives FDA Approval Of ZEVASKYN Marking A First

Things went very well today for Abeona Therapeutics because it had received FDA approval of the first and only...

Positive Sasanlimab Data From Pfizer Could Bring New Medicine For High-Risk Bladder Cancer

Pfizer seemed to have a good win over this past weekend because it presented positive results from its phase...

Caribou Cuts Workforce And Puts Focus To lead Oncology Candidates

Caribou Biosciences announced today that it will reprioritize its pipeline and focus on two specific clinical candidates. These two...

Genentech Aims For DECODE Platform From Repertoire In $765 Million Deal

Genentech, a subsidiary of Roche, just established a deal today with a biotech by the name of Repertoire Immune...

Bristol-Myers Squibb Fails Phase 3 Study With Cobenfy

Just today, Bristol-Myers Squibb announced that it had failed to achieve the primary endpoint of its phase 3 ARISE...

In Flight To Enact Strategic Alternatives, Tempest Cuts 80% of its Workforce

Earlier this month, Tempest Therapeutics announced that it would explore strategic alternatives for its oncology pipeline of assets. Specifically,...

Eli Lilly’s Orforglipron Delivers Efficacy Similar To That Of Injectable GLP-1 Drugs

Eli Lilly just can't seem to stop with the continuous wins in the clinic because just today it announced...

Despite Primary Endpoint Falling Short, Sanofi Moving Amlitelimb Forward

Things didn't go very well today for Sanofi, because it announced that its phase 2 TIDE-Asthma study failed to...

Mural Oncology Mulls Strategic Alternatives After Latest Failure With IL-2 Candidate

Things didn't go as planned with Mural Oncology in terms of another shot on goal for its lead IL-2...

.cls-businesslogo{fill:#4db2ec;}.cls-businesslogo2{fill:#2783ba;}.cls-businesslogo3{fill:#fff;}

.cls-businesslogo{fill:#4db2ec;}.cls-businesslogo2{fill:#2783ba;}.cls-businesslogo3{fill:#fff;}

.cls-businesslogo{fill:#4db2ec;}.cls-businesslogo2{fill:#2783ba;}.cls-businesslogo3{fill:#fff;}

.cls-businesslogo{fill:#4db2ec;}.cls-businesslogo2{fill:#2783ba;}.cls-businesslogo3{fill:#fff;}

today

around the world

spotlight

latest articles

.cls-businesslogo{fill:#4db2ec;}.cls-businesslogo2{fill:#2783ba;}.cls-businesslogo3{fill:#fff;}

most viewed

trending right now